Accelerating the discovery and validation of biomarkers for neurodegenerative diseases – The EPND Initiative

BMD is participating in a new European initiative that will build a collaborative platform for data and sample sharing, to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

EPND (European Platform for Neurodegenerative Diseases)  will begin a five-year effort to establish a self-sustaining network that will support the discovery, harmonization, storage and analysis of high-quality clinical samples and data from neurodegenerative disease research.

The Innovative Medicines Initiative (IMI) works to improve health by speeding up the development of, and patient access to innovative medicines, particularly in areas where there is an unmet medical or social need. IMI connects the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

The IMI is the world’s biggest public-private partnership (PPP) in the life sciences, and is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). More information can be found at

Read more about it:

Stay tuned for more updates by following us on social media:

Comments are closed.